ConvaTec now expects InnovaMatrix revenue of £5 million to £10 million for the full year, compared with previous expectations, representing an estimated 2.5% headwind to annual group revenue growth. The company expects the product to approach breakeven in the second half as U.S. market conditions stabilize. ConvaTec maintained its 2026 targets after delivering 5% first-half organic revenue growth excluding InnovaMatrix, 6% adjusted EPS growth and a 21.2% operating margin. Management expects double-digit Infusion Care growth in the second half and high-single-digit growth for the full year. The article "ConvaTec Group H1 Earnings Call Highlights" was originally published by MarketBeat.